Paola Anselmo, Radiation Oncologist at S. Maria Hospital, Terni, shared a post on X, shared a recent article she and her colleagues co-authored, adding:
“I’m proud to share the update of the STARTNEWERA phase II trial!
In press on IJROBP the 5-year survival and safety of SAbR in unresectable LA-NSCLC patients unfit for concurrent RT-ChT: focus on patterns of local recurrence.”
Title: 5-year survival and safety of stereotactic ablative radiotherapy in unresectable locally advanced non-small cell lung cancer patients unfit for concurrent radio-chemotherapy:focus on patterns of local recurrence from the START-NEW-ERA non-randomized phase II trial
Authors: Fabio Arcidiacono, Paola Anselmo, Michelina Casale, Cristina Zannori, Fabio Loreti, Benedetta Enrico, Valentina Tassi, Alessandro Di Marzo, Marco Italiani, Gustavo Arruda Viani, Ernesto Maranzano, Fabio Trippa.
Read the full article on The International Journal of Radiation Oncology.
Joe Y Chang, Endowed Texas 4000 Distinguished Professor and Director of Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center, shared this post on X adding:
“With SABR 40-45 GY in 5 FX in medical inoperable, not suitable for concurrent chemo/RT stage III NSCLC, 46% OS and 26% PFS at 5-year is comparable to PACIFIC study (43% and 33% respectively).
Surprisingly, no greater than or equal to Grade 3 complications.
SABR GTV, no CTV, PTV 5 mm is the key?”
Read more posts featuring Joe Y Chang, on OncoDaily.
